Acetylsalicylic acid in primary prevention among patients with arterial hypertension
https://doi.org/10.15829/1560-4071-2013-5-81-87
Abstract
Arterial hypertension (AH) remains one of the most prevalent cardiovascular diseases (CVD) and is an important risk factor of severe, often fatal complications. CVD prevention in AH patients is a complex task, including not only blood pressure reduction, but also targeting additional risk factors. The HOT study was the first attempt to assess the effects of acetylsalicylic acid (ASA) on CVD risk in AH patients. It was shown that ASA reduced the risk of major cardiovascular events (non-fatal acute myocardial infarction (MI), non-fatal stroke, and cardiac death) by 15% (p=0,03). The risk of MI was reduced by 36% (p=0,02). In order to implement the HOT study results in the clinical practice, additional data analyses were performed, which demonstrated that ASA benefits were the most pronounced in patients with creatinine levels >150 mmol/l. The evidence from the HOT study, including the subgroup analysis results, has been included in the latest guidelines on AH management.
About the Authors
A. V. Melekhov
Hospital Therapy Department No. 2, N. I. Pirogov Russian National Medical
Research University, Moscow, Russia
Russian Federation
Russian Federation
E. E. Ryazantseva
Hospital Therapy Department No. 2, N. I. Pirogov Russian National Medical
Research University, Moscow, Russia
Russian Federation
Russian Federation
References
1. Mancia G., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 2013. 31 (7):1281–357.
2. Costanzo S., et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction — the impact of migration as a model of gene-environment interaction project. J Hypertens, 2008. 26 (12):2303–11.
3. Wolf-Maier K., et al., Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA, 2003. 289 (18):2363–9.
4. Redon J., et al., Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J, 2011. 32 (11):1424–31.
5. European Society of Hypertension-European Society of Cardiology Guidelines, C., 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003. 21 (6):1011–53.
6. Mansia G., et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press, 2007. 16 (3):135–232.
7. Britton K. A., Gaziano J. M., Djousse L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail, 2009. 11 (12):1129–34.
8. Kalaitzidis R. G., Bakris G. L. Prehypertension: is it relevant for nephrologists? Kidney Int, 2010. 77 (3):194–200.
9. Lawes C. M., et al. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. Hypertension, 2003. 42 (1):69–75.
10. Brown D. W., Giles W. H., Greenlund K. J. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens, 2007. 20 (3):338–41.
11. Vishram J. K., et al. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. Hypertension, 2012. 60 (5):1117–23.
12. Conroy R. M., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 2003. 24 (11):987–1003.
13. Antithrombotic Trialists, C., et al., Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009. 373 (9678):1849–60.
14. Hansson L., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998. 351 (9118):1755–62.
15. Zanchetti A., et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens, 2002. 20 (11):2301–7.
16. Jardine M. J., et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol, 2010. 56 (12):956–65.
17. Rothwel P. M., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 2012. 379 (9826):1602–12.
18. Diagnostics and treatment of arterial hypertension. Russian recommendations (fourth edition). System hypertensions 2010; 3:5–26. (Диагностика и лечение артериальной гипертензии. Российский рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3:5–26).
19. Vandvik P. O., et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141 (2 Suppl): p. e637S-68S.
Review
For citations:
Melekhov A.V., Ryazantseva E.E. Acetylsalicylic acid in primary prevention among patients with arterial hypertension. Russian Journal of Cardiology. 2013;(5):81-87. (In Russ.) https://doi.org/10.15829/1560-4071-2013-5-81-87
Views:
2030
Email this article 